|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0120 AUD | -7.69% |
|
-7.69% | -20.00% |
| 28/05 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 27/05 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 6.67M 4.59M 4.02M 3.71M 3.47M 6.52M 434M 44.66M 17.24M 214M 17.24M 16.86M 743M | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 9.44M 6.5M 5.69M 5.25M 4.91M 9.23M 614M 63.21M 24.4M 303M 24.4M 23.87M 1.05B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 16/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | -7.69% | ||
| 1 week | -7.69% | ||
| 3 months | +9.09% | ||
| 6 months | -20.00% | ||
| Current year | -20.00% |
| 1 week | 0.01 | 0.01 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.69% | -7.69% | -25.00% | -71.43% | 4.59M | ||
| -0.66% | -0.29% | +11.15% | +77.11% | 47.58B | ||
| -0.96% | +0.89% | +51.10% | +104.99% | 35.47B | ||
| +0.78% | +2.25% | -2.69% | +44.38% | 12.42B | ||
| -0.78% | +0.04% | +12.39% | +90.82% | 11.83B | ||
| +2.46% | -2.31% | +32.29% | +118.03% | 8.79B | ||
| +1.41% | +2.60% | +22.40% | +45.37% | 7.09B | ||
| -0.91% | +2.53% | +53.18% | -8.37% | 6.99B | ||
| +0.81% | +1.14% | +25.69% | +226.08% | 6.53B | ||
| +9.12% | +6.89% | -29.64% | +6.47% | 5.4B | ||
| Average | +0.36% | +1.04% | +15.09% | +63.35% | 14.21B | |
| Weighted average by Cap. | +0.10% | +1.73% | +23.07% | +83.25% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.5M 3.07M 2.83M 2.64M 4.98M 331M 34.08M 13.15M 163M 13.16M 12.87M 567M | 1.19M 819K 717K 662K 618K 1.16M 77.42M 7.96M 3.07M 38.19M 3.08M 3.01M 133M |
| Net income | -5.8M -3.99M -3.49M -3.23M -3.01M -5.67M -377M -38.82M -14.99M -186M -14.99M -14.66M -646M | -5.94M -4.09M -3.58M -3.31M -3.09M -5.81M -387M -39.79M -15.36M -191M -15.36M -15.03M -662M |
| Net Debt | 759K 522K 457K 422K 394K 742K 49.38M 5.08M 1.96M 24.36M 1.96M 1.92M 84.57M | 2.77M 1.91M 1.67M 1.54M 1.44M 2.71M 180M 18.55M 7.16M 88.96M 7.16M 7.01M 309M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/06/26 | $0.0120 | -7.69% | 622,468 |
| 29/06/26 | $0.0130 | -7.14% | 237,052 |
| 26/06/26 | $0.0140 | +7.69% | 789,030 |
| 25/06/26 | $0.0130 | -7.14% | 1,327,517 |
| 24/06/26 | $0.0140 | +7.69% | 369,855 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















